OncoNano Medicine will present preclinical data of a dual-activating STING agonist at the Society for Immunotherapy of Cancer (SITC) annual meeting.

Southlake, Texas–(business wire)–OncoNano Medicine, Inc. announced today that it has presented data on its preclinical candidate ONM-501 at the 37th Annual Meeting of the Society for Cancer Immunotherapy (SITC) in Boston, Massachusetts. ONM-501 is his OncoNano’s lead treatment program under development, with dual activation STING (centemulator of ofTerferon G.enes) agonist is progressing toward first human trials, which are expected to begin in the first half of 2023.

Previously published data demonstrate a differentiated mechanism of ONM-501, with dual ‘burst’ and ‘sustained’ activation of STING, enhanced cytosolic delivery, and OnocoNano’s unique STING activation We demonstrate tumor retention by encapsulation of an endogenous STING agonist of cGAMP with OMNI™ polymeric micelles. These two mechanisms act in concert to activate STING and potentiate this activation, and have been shown to be single-agent in multiple preclinical mouse models with both ‘hot’ and ‘cold’ tumor microenvironments. As a therapy and in combination with anti-PD1, it provides potent anti-tumor effects. In vivo PD analysis confirmed STING activation, enhanced tumor lymphocyte infiltration, and tumor PD-L1 upregulation by ONM-501, demonstrating ONM-501’s target binding activity in multiple species, and rodent and non-target binding activity. High tolerance in human primates was demonstrated. It has become a promising therapeutic candidate for clinical evaluation.

“The results presented here support many hypotheses regarding the potential of ONM-501 to provide a potent therapeutic index of immunostimulatory STING activity that is distinct from other STING agonists. The continuing strong preclinical results highlight its potential as a monotherapy and in combination with anti-PD1 in multiple ‘hot’ and ‘cold’ murine syngeneic tumor models,” Kartik said. Krishnan said. MD, PhD, Chief Medical Officer of OncoNano. “In 2023, he looks forward to introducing ONM-501 into his clinic as we continue our mission to bring important new therapies to patients in need.”

Presentation overview


ONM-501, a multivalent STING agonist, exhibits antitumor effects by increasing tumor T-cell infiltration in mice and is well tolerated in rats and non-human primates


November 10-11, 2022


9am-9pm EST


Poster Hall, Boston Convention and Exhibition Center, Boston, Massachusetts

About Onconanomedicine

OncoNano Medicine is developing a new class of products that utilize the principle of molecular cooperativity in their design, using pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to assist patients across the cancer care continuum, including solid tumor therapeutics, agents for real-time image-guided surgery, and activating the body’s immune system to including immuno-oncology drug platforms targeting cancer.

OncoNano’s lead development candidate is pegshitacyanin, a novel fluorescent nanoprobe using the ONBOARD platform, currently being investigated in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries. His second development program for OncoNano, his ONM-501, the next generation of his STING (Stimulator of INterferon Genes) agonist, is on track for first human trials in the first half of 2023. Pegshitacyanin and his ONM-501 from the Texas Institute of Cancer Prevention. For more information, please visit

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button